Chronic Chemotherapy-induced Neuropathic Pain, Chronic Chemotherapy-induced Pain, Chronic Chemotherapy-induced Peripheral Neuropathy, Chronic Neuropathic Pain, Postoperative, Chronic Pain, Postoperative
Conditions
Brief summary
To understand pain pathophysiology in terms of risk factors and protective mechanisms ranging from molecular pathways to societal impacts.
Detailed description
Pain and loss of function are intimately associated with the reaction of the nervous system to neural damage. A lesion to the somatosensory nervous system caused by mechanical trauma, metabolic disease, neurotoxic chemicals, infection or tumor invasion may give rise to neuropathic pain. Neuropathic pain affects around 8% of the population and may negatively impact the individual's quality of life; moreover, the condition leads to significant costs to the healthcare system and society. Not all subjects with such a lesion develop neuropathic pain, and those who do develop neuropathic pain have varying degrees of symptom severity, impact and outcomes and may respond unpredictably to treatment. The interaction between genetics and environmental and clinical factors in a susceptible individual most likely contribute to the variation in pain prevalence and severity. A better understanding of the exact nature of these risk factors and their interactions will ultimately improve the patients' health, both in terms of recognizing patients at risk and identifying new treatment modalities. Genetic, neurophysiological and psychological factors all influence the risk of developing persistent pain. It is therefore possible to describe a genetic, neurophysiological and psychological profile, in particular in patients experiencing neuropathic pain after surgery and/or neurotoxic chemotherapy.
Interventions
PROCEDUREThoracic surgery for lung cancer
Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
Sponsors
DOLORisk Consortium
Aarhus University Hospital
Danish Pain Research Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female subjects. * Age ≥18 years. * Patients scheduled for lung cancer resection performed via thoracoscopy and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof. * Willingness and ability to comply with study procedures as judged by the site investigator/manager. * Expected availability for follow-up throughout the study, i.e., \ 12 months. * Willingness to voluntarily sign and date the study-specific informed consent form.
Exclusion criteria
* Mental incapacity or language barriers precluding adequate understanding of study procedures. * Current alcohol or substance abuse according to the site investigator's medical judgement. * Unsuitability for participation in the study for any other reason, e.g. due to a significant serious underlying condition (e.g. other cancer or AIDS), as determined by the site investigator/manager.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Chronic Neuropathic Pain, Postoperative | 12 months after surgery | Neuropathic pain grading system, Finnerup et al. 2016 will be used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Chronic Chemotherapy-induced Peripheral Neuropathy | 12 months after surgery | For case definition of neuropathy, Tesfaye et al. 2010 will be used. |
| Chronic Chemotherapy-induced Neuropathic Pain | 12 months after surgery | Neuropathic pain grading system, Finnerup et al. 2016 will be used. |
| Acute Postoperative Pain | 0-5 days after surgery | Rest and movement-evoked postoperative pain measured on an 11-point NRS |
| Area of peri-incisional hyperalgesia | 0-5 days after surgery | Quantification of peri-incisional hyperalgesia - area and worst pin-prick pain intensity is assessed with a 5.88 monofilament |
Countries
Denmark
Outcome results
None listed